NUEDEXTA Drug Patent Profile

When do Nuedexta patents expire, and when can generic versions of Nuedexta launch?

Nuedexta is a drug marketed by Avanir Pharms and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in twenty-one countries.

The generic ingredient in NUEDEXTA is dextromethorphan hydrobromide; quinidine sulfate. There are twenty-three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the dextromethorphan hydrobromide; quinidine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nuedexta

A generic version of NUEDEXTA was approved as dextromethorphan hydrobromide; quinidine sulfate by ACTAVIS ELIZABETH on October 10^th, 2017.

Summary for NUEDEXTA

International Patents:	75
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	12
Patent Applications:	130
Drug Prices:	Drug price information for NUEDEXTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUEDEXTA
What excipients (inactive ingredients) are in NUEDEXTA?	NUEDEXTA excipients list
DailyMed Link:	NUEDEXTA at DailyMed

See drug prices for NUEDEXTA

Recent Clinical Trials for NUEDEXTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prilenia	PHASE3
Ferrer Internacional S.A.	PHASE3
All India Institute of Medical Sciences, Bhubaneswar	Phase 4

See all NUEDEXTA clinical trials

Pharmacology for NUEDEXTA

Drug Class	Antiarrhythmic Cytochrome P450 2D6 Inhibitor Sigma-1 Agonist Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Mechanism of Action	Cytochrome P450 2D6 Inhibitors Sigma-1 Receptor Agonists Uncompetitive NMDA Receptor Antagonists

Paragraph IV (Patent) Challenges for NUEDEXTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUEDEXTA	Capsules	dextromethorphan hydrobromide; quinidine sulfate	20 mg/10 mg	021879	1	2011-03-07

US Patents and Regulatory Information for NUEDEXTA

NUEDEXTA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	AB	RX	Yes	Yes	7,659,282

Expired US Patents for NUEDEXTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	RE38115
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	5,166,207
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	8,227,484
Avanir Pharms	NUEDEXTA	dextromethorphan hydrobromide; quinidine sulfate	CAPSULE;ORAL	021879-001	Oct 29, 2010	5,206,248

EU/EMA Drug Approvals for NUEDEXTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Jenson Pharmaceutical Services Limited	Nuedexta	dextromethorphan hydrobromide, quinidine sulfate	EMEA/H/C/002560Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.	Withdrawn	no	no	no	2013-06-24

International Patents for NUEDEXTA

See the table below for patents covering NUEDEXTA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2114267	UTILISATION D'UN INHIBITEUR D'OXYDASE AVEC LE DEXTROMETHORPHANE POUR TRAITER LES TOUX ET LES DERMATITES REBELLES (USE OF OXIDASE INHIBITOR WITH DEXTROMETHORPHAN TO TREAT INTRACTABLE COUGHING AND DERMATITIS)
Canada	2712821	UTILISATION D'UN INHIBITEUR D'OXYDASE AVEC LE DEXTROMETHORPHANE POUR TRAITER LES TOUX ET LES DERMATITES REBELLES (USE OF OXIDASE INHIBITOR WITH DEXTROMETHORPHAN TO TREAT INTRACTABLE COUGHING AND DERMATITIS)
Austria	399553
Australia	2003251971	PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Supplementary Protection Certificates for NUEDEXTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539166	C300626	Netherlands		PRODUCT NAME: COMBINATIE VAN: (A) DEXTROMETHORFAN, DESGEWENST; REGISTRATION NO/DATE: EU/1/13/833 20130624
1539166	CR 2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
1539166	CA 2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624
1539166	C20130030 00105	Estonia		PRODUCT NAME: DEKSTROMETORFAAN / KINIDIIN;REG NO/DATE: K(2013)4096 (LOPLIK) 26.06.2013

Nuedexta (dextromethorphan/quinidine): Market dynamics and financial trajectory (US and selected markets) for the pseudobulbar affect therapy

Last updated: May 28, 2026

Nuedexta (dextromethorphan/quinidine) is a niche specialty CNS product in the US built on chronic, symptom-targeted use for pseudobulbar affect (PBA). Market outcomes have tracked (1) diagnosis and prescribing adoption, (2) payer coverage and prior-authorization friction, and (3) unit-cost pressure from the approach of key exclusivity and follow-on generic and reformulation risk. Financial trajectory is dominated by US sales, with growth constrained by limited eligible patient population and competitive pressure from off-label and alternative on-label symptom therapies for related neurologic conditions.

Nuedexta market size, growth drivers, and unit economics

Quick answer: Nuedexta’s market is defined by the addressable PBA population in MS, ALS, dementia-spectrum disorders, and other neurologic diseases. Growth drivers are physician awareness, payer contracting strength, and stable adherence in a long-duration indication. The main headwinds are constrained patient prevalence, neurologist and psychiatrist channel mix, and premium drug price tolerance.

Where demand comes from in PBA

PBA is prevalent in neurologic disease states with impaired affect control. Nuedexta’s commercial value depends on:

• Continued identification of PBA within established neurologic patient bases
• Clinician acceptance of quinidine-containing therapy (monitoring and contraindication management)
• Payer acceptance for chronic maintenance dosing

Key unit economics: what determines profitability

The financial profile is typical of specialty CNS drugs:

• High gross margin potential initially due to exclusivity
• Margin compression risk from generic entry, lower-cost alternatives, and dispensing-channel contracting
• Budget impact concerns for neurologic payers due to long-duration therapy

Revenue volatility drivers

Nuedexta revenue can swing due to:

• Coverage changes by large payers (PA criteria and step edits)
• Generic substitution pressure if patent protection weakens or if label-protected formulations face carve-out challenges
• Clinical guideline updates that shift preference toward competing agents or off-label SSRI/SNRI approaches

What competitive landscape impacts Nuedexta pricing and share?

Quick answer: Competition is shaped by (1) alternative pharmacotherapies used off-label for PBA and (2) direct branded or branded-generics in the dextromethorphan/quinidine space if product life-cycle pressure escalates. Even when direct competitors do not match Nuedexta’s labeled position, substitution happens through payer policies and clinician preference.

On-label and off-label substitutes

Common competitive substitution pathways include:

• Off-label antidepressants (SSRIs/SNRIs) used for affective symptoms in neurologic disease
• Symptom-management strategies and non-pharmacologic pathways that reduce medication persistence
• Other CNS agents used for mood lability or behavioral symptoms in dementia and neurodegeneration

Specialty channel competition

Because neurologists and neurologic specialists gate adoption, channel influence matters:

• Neurology-focused formularies drive share
• Hospital system contracts can impose tiering and prior authorization rules
• Prescription abandonment occurs when monitoring requirements or contraindications are hard to manage

How payer negotiations affect net price

The post-launch phase typically exposes net price erosion from:

• Contracting at PBM and health-system level
• Increased use of plan formularies with step edits
• Expanded PA rules that tighten access

How does exclusivity risk change Nuedexta’s revenue outlook?

Quick answer: Nuedexta’s revenue outlook is sensitive to generic entry risk tied to patent estate strength and exclusivity windows for both active ingredient combination and formulation/dosing. As those timelines approach, wholesalers and PBMs increase preemptive contracting and reserve market share for lower-cost supply.

Sources of exclusivity protection

For combination products like dextromethorphan/quinidine, protection typically spans:

• Composition of matter for each component or the combination
• Method-of-use or dosing regimens
• Formulation and bioavailability-related modifications
• Potential patent thickets covering manufacturing methods

What to watch as financial indicators

Near-term financial trajectory is most responsive to:

• Paragraph IV filings and litigation timelines (if any affect supply)
• Settlement terms that define launch dates for would-be challengers
• Any FDA label changes that create new regulatory exclusivity opportunities or change generic feasibility

What is the FDA regulatory status of Nuedexta and how does it affect sales?

Quick answer: Nuedexta is an FDA-approved combination product indicated for PBA. The regulatory profile affects sales through label strength, Risk Evaluation and Mitigation Strategy requirements if applicable, and whether generic applicants can rely on FDA-listed bioequivalence and sameness rules.

FDA labeling and commercial implications

Key regulatory factors that typically shape market outcomes:

• Tight contraindications and interaction warnings that require clinician screening
• Dosing complexity that affects initiation and persistence
• Label language that defines PBA diagnostic boundaries and limits expansion to broader emotional lability

Generic pathways that matter

Generic adoption depends on whether challengers can:

• Demonstrate bioequivalence without crossing protected formulation constraints
• Avoid infringing listed patents
• Gain acceptance for the same indication under FDA rules

What patent litigation and Paragraph IV challenges could change Nuedexta’s financial trajectory?

Quick answer: Any patent litigation or Paragraph IV challenge involving Nuedexta is a direct leading indicator for a step-change in competitive intensity. The timing and outcome of such matters dictate whether generic competition arrives earlier through an at-risk launch, later through a delayed entry agreement, or not at all.

How litigation maps to revenue

Revenue impact usually follows this pattern:

• Pre-filing and filing signals trigger payer contracting adjustments
• Litigation timelines create uncertainty that can delay generic purchasing and change branded discounting behavior
• Settlement can lock in a defined generic start date or carve-out

Portfolio dynamics

The magnitude of revenue impact depends on:

• Number of Orange Book-listed patents
• Whether key patents cover the combination at a composition level versus only formulations or use
• Strength of the defendant’s patent positions and enforceability

What formulations and dosing strengths drive Nuedexta prescribing and payer coverage?

Quick answer: For Nuedexta, dosing initiation schedules and maintenance dosing drive adherence and medical-legal comfort, which in turn affect payer utilization. Any protected dosing or formulation features raise the barrier to safe substitution and can delay generic take-up.

Dose titration and persistence

PBA is chronic, so the commercial model depends on:

• Tolerability during initiation
• Long-term adherence
• Reduced discontinuations due to adverse events or drug interactions

Formulation barriers

Combination products can face practical barriers:

• Manufacturing controls for consistent bioavailability
• Stability and dissolution profiles affecting interchangeability
• Bioequivalence sensitivity for fixed-dose combinations

How strong is Nuedexta’s patent estate versus likely generic entry risk?

Quick answer: The patent estate strength determines whether generic competition is delayed until the end of listed exclusivity or whether carve-outs enable earlier entry. Combination and formulation thickets can extend exclusivity beyond basic composition-of-matter expiration.

Patent strength indicators that map to business outcomes

• Number of independently listed Orange Book patents for the same product
• Remaining term on the most “central” patents (combination/formulation)
• Litigation history suggesting enforceability risks or adverse rulings
• Settlement outcomes that align with court and FDA timelines

Nuedexta financial trajectory: sales drivers, margin structure, and key inflection points

Quick answer: Nuedexta’s financial trajectory reflects a blend of stable specialty demand and time-limited protection. Net sales rise with diagnosis conversion and formulary placement early in the lifecycle. Mid-to-late lifecycle performance becomes increasingly sensitive to payer net price erosion, competitive pressures, and the timing of any generic supply availability.

What typically drives early-stage growth

• Prescriber education and PBA identification
• Coverage uptake and reduced administrative barriers
• Increased brand awareness within neurology clinics

What typically drives mid-to-late stage performance

• Net price declines via contracting cycles
• Persistence and adherence effects from real-world tolerability
• Reduced growth as addressable diagnoses saturate

What could create a near-term inflection

• A significant change to PA criteria at major payers
• A competitive supply change via generics or reformulated substitutes
• Litigation outcomes affecting label-protected entry windows

Which companies are positioned to win share if Nuedexta faces generic pressure?

Quick answer: In practice, share capture typically comes from the first-to-launch generic that can obtain favorable FDA approval and distribution contracting, supported by PBM and pharmacy channel readiness. Incumbents and authorized generics can also compete through delayed or bundled launch strategies following settlements.

Channel outcomes

• Wholesaler stocking and hospital formularies can shift quickly after launch dates
• PBM edits can reduce branded persistence if no longer cost-effective
• Retail pharmacy substitution policies accelerate volume movement to lower priced equivalents

Does Nuedexta have biosimilar risk or only generic small-molecule risk?

Quick answer: Nuedexta is a small-molecule fixed-dose combination, so it faces generic competition risk, not biosimilar risk.

Implications

• FDA pathway is based on generic drug approval and bioequivalence
• Market disruption timing is driven by patent status and exclusivity windows rather than biologics-focused interchangeability

How does Nuedexta compare with other PBA therapies on market positioning and adoption?

Quick answer: Nuedexta’s differentiation is labeled specificity for PBA, which supports insurance coverage and clinician adoption. Alternative therapies compete through off-label use and insurance preference patterns rather than labeled equivalence.

Competitive adoption dynamics

• Labeled status reduces clinician justification burden
• Off-label therapies face variability in payer authorization and documented practice patterns
• Fixed-dose combination supports simplicity relative to multi-drug off-label regimens but increases contraindication complexity

Key Takeaways

• Nuedexta’s market is a specialty CNS niche defined by chronic PBA identification in neurologic disease populations.
• Growth is driven by diagnosis conversion, physician education, payer contracting, and persistence; revenue sensitivity increases mid-to-late lifecycle through net price erosion.
• Exclusivity and patent estate status are central to the revenue outlook because generic small-molecule entry would produce step-change competitive pressure.
• Any Paragraph IV filings, litigation, or settlement terms are primary leading indicators for revenue inflection and payer behavior shifts.

FAQs

1. How long do patent protections typically extend for dextromethorphan/quinidine fixed-dose combinations like Nuedexta?
2. What prior-authorization criteria most commonly restrict Nuedexta access at large US payers?
3. What real-world factors most affect Nuedexta persistence in chronic PBA management?
4. How do PBM contracting strategies usually change as a niche specialty drug approaches generic entry?
5. What factors most influence generic launch timing for combination small-molecule products with multiple Orange Book patents?

References

1. FDA. “Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) Prescribing Information.” US Food and Drug Administration.
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.

DrugChatter Q&A for NUEDEXTA

Nuedexta loss of exclusivity?
When does nuedexta go generic?
Nuedexta star trial listing with sf 36?
Nuedexta without insurance?
Nuedexta cost without insurance?